Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 167% above its 5-year average of 37.50%, near the high end of its 5-year range (-3239.22%–100.00%).
66.67% above its 12-month average of 60.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
60.00%
GROSS MARGIN AVG 3Y
46.15%
GROSS MARGIN AVG 5Y
37.50%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+66.67%
CURRENT VS 3Y AVG
+116.67%
CURRENT VS 5Y AVG
+166.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+142.69%
vs the sector median at left
Korsana Biosciences, Inc.
Market Cap
$148.73M
Gross Margin
100.00%
TTM Avg
60.00%
3Y Avg
46.15%
5Y Avg
37.50%
Market Cap
$148.64M
Gross Margin
-227.62%
TTM Avg
-63.81%
3Y Avg
-25.20%
5Y Avg
-26.93%
Market Cap
$148.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$149.36M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
1.51%
Market Cap
$146.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-76.15%
Market Cap
$151.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
Market Cap
$146.27M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $148.73M | 100.00% | 60.00% | 46.15% | 37.50% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -227.62% | -63.81% | -25.20% | -26.93% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | 0.00% | 0.00% | 0.00% | 1.51% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 0.00% | 0.00% | 0.00% | -76.15% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | 0.00% | 0.00% | 0.00% | -29.98% |
| Codexis, Inc. (CDXS)vs › | $146.28M | 83.71% | 79.64% | 78.40% | 78.75% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 62.53% | 65.36% | 65.75% | 64.06% |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | 0.00% | 0.00% | 0.00% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | -3239.22% |
| 2022-03-31 | -1270.32% |
| 2021-12-31 | -1862.10% |
| 2021-09-30 | -1920.69% |
| 2021-06-30 | -301.80% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -8991.73% |
| 2020-09-30 | -3325.75% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | -1559.27% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
